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Introduction  
Retinoblastoma is the most common primary intraocular malignancy of 
infancy and childhood1. It is the second most common intraocular malignant 
tumour of all age groups next to choroidal melanoma. It is the tenth most 
common cancer in childhood in US and accounts for 3% of all childhood 
cancers2. Retinoblastoma has cumulative life time incidence of 1:18000 to 
30,000 live births world wide3. Indian studies have shown the incidence of the 
tumour in India as 1:15000 live births (Viswananth et al).  
Retinoblastoma is a highly malignant tumour that arises from the 
neuroectodermal cells (most commonly from the nuclear layers of retina) that 
are destined to become retinal photoreceptors. Retinoblastoma represents the 
phenotypic expression of an abnormal or absent tumour suppressor gene known 
as retinoblastoma gene RB1 the first tumour suppressor gene to be identified 20. 
Retinoblastoma most often presents in early child hood as leucokoria or 
white reflex. The manner of intra ocular presentation, extraocular extension, 
pattern of metastases and recurrence, ocular complications and associated 
malignancies makes diagnosis of retinoblastoma one of the most challenging 
problems of paediatric ophthalmology. To ensure appropriate therapy 
retinoblastoma must be differentiated from a host of benign lesions that 
simulate it. The diagnosis must be established rapidly to permit maximum 
ocular salvage and to minimize tumour associated mortality.  
Prior to this century, retinoblastoma was a uniformly fatal disease4.With 
the advances in diagnosis and treatment, survival have raised from 30% in 
1930s to nearly 95% in 1990s in most developed countries5. 
Recent advanced in our understanding of retinoblastoma have led to trials of 
new treatment modalities aimed at decreasing morbidity and continuing excellent 
survival.  
RETINOBLASTOMA IN INDIA  
India is one of the countries that have the largest numbers of 
individuals affected with retinoblastoma. World wide the incidence of 
retinoblastoma has been reported to be 1 in 18,000 live births. In India, which 
has the highest number of babies born in the world, 1,500 children are born 
every year with retinoblastoma.  
This high number of cases found in India gives an opportunity for us to 
study these cases and to evaluate the efficacy and outcome of different 
treatment modalities available. Amongst problem facing in treating these cases, 
unawareness, illiteracy, poverty, cost and lack of compliance are issues to be 
tackled. 
PURPOSE OF THE STUDY 
Only few studies about Retinoblastoma have been published from India. 
Of the few studies only 4 studies have studied the demographic pattern, modes 
of presentation, clinical features of retinoblastoma, problems and perspectives 
in diagnosis and treatment, survival of retinoblastoma cases in India 64, 65, 66, 67. 
The studies have been from western and northern India. The probable reason 
for having such a few studies could be because of availability of treatment 
modality for retinoblastoma in only few places in India. 
The Aravind Eye Care System is one of the few tertiary eye care centers 
in India that has all facilities for diagnosis and treatment of Retinoblastoma and 
the hospital is also involved in research on its various aspects. The hospital acts 
is one of the main referral hospital in south India. A prospective study 
conducted in cases of Retinoblastoma treated in this hospital would give a good 
idea about demography, main mode of presentation, clinical features, 
acceptance and response to treatment of the cases in this part of the country and 
would help us in proposing new strategies or strengthening existing ones for 
earlier diagnosis and opting better treatment methods in treatment of 
Retinoblastoma.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
The first description of a tumor resembling retinoblastoma was by Peter 
Pawius of Amsterdam6. He wrote of a malignancy invading the orbit, the 
temporal region, and the cranium, a picture now strongly suggestive of 
untreated retinoblastoma. The tumor was described to be filled with a 
"substance similar to brain tissue mixed with thick blood and like crushed 
stone."  
In 1805, William Hey coined the term fungus naematodes, which he 
used to describe a fungating mass affecting the globe of the eye and destroying 
its internal organization In 1809, the Scottish surgeon James Wardrop pieced 
together the random isolated facts and observations of previous authors. Despite 
not having a microscope at his disposal, his meticulous dissection and astute 
interpretations of some of these eyes led him to conclude that in most instances 
the tumor arose from the retina. Wardrop documented the extension of the 
tumor to the optic nerve and brain7. Later, he described metastasis to different 
parts of the body.  
In 1836, Langenbech, Robin, and Nystin of Paris confirmed by 
microscopic studies that the tumor definitely arose from the retina.  
In 1864, Virchow named it a glioma of the retina, supporting glial cells 
as the cell of origin of the tumor6  
In 1891, Flexner of Johns Hopkins was first to notice rosettes within the 
tumor. A few years later in 1897, Wintersteiner concurred with Flexner and 
proposed the name neuroepithelioma noting its resemblance to rods and cones 
and traced one tumor to the photoreceptor cell layer6. Presently, their names are 
attached to these rosettes..  
Most cells comprising the tumor histologically resembled the cells of an 
undifferentiated retina of the embryo called retinoblasts. This resemblance 
prompted Veorhoff8 to coin the term retinoblastoma, which later was adopted 
by the American Ophthalmological Society in 1926 as a general term for this 
entity.  
In 1970, Tso and colleagues established that the tumor arises from 
photoreceptor precursors9 
Retinoblastoma was one of the prototypic models demonstrating the 
genetic etiology of cancer. Though it was recognized as a genetic problem in 
beginning of this century ,the ideas that were significant to understanding this 
cancer came in 1970.In early 1970s Knudson10 used knowledge about the 
clinical presentation of retinoblastoma and the number of cell divisions in 
human retina to develop a “two hit” mutational model. The Knudson’s  
hypothesis was eventually proved correct with discovery of the RB 1 gene. 
In 1980, the gene causing retinoblastoma was identified by a research 
group in Boston.  
Exciting discoveries have occurred in the past decade regarding the 
molecular genetic basis for this disease. The tumor suppressor RB gene has 
now been cloned and there exists a potential for prevention and other treatment 
advances arising from these discoveries. The most difficult problem posed in 
treatment of the   tumors will probably be solved only by molecular genetics 
approaches. 
EVOLUTION OF TREATMENT FOR RETINOBLASTOMA  
Prior to this century retinoblastoma was a uniformly fatal disease. The 
development of ophthalmoscope, general anesthesia and surgical enucleation 
improved prognosis so that survival rate exceeded 90% in most developed 
countries5. The initial treatment in the 19th century was enucleation. Though it 
was a life saving procedure, in many cases it eliminated any chance of vision in 
the affected eye and it was associated with usual problems of anophthalmic 
socket. 
The radiation therapy was advocated in early part of 19th century ,but 
the first long term survivor after radiation therapy was a patient treated by 
Verhoeff in 1921 at the Massachusetts Eye and Ear infirmary11. The modern 
Era of radiation therapy was introduced by Reese and colleagues in the 1930s 
and 1940s12.The external beam Radiotherapy(EBRT) allowed salvage of many 
eyes ,some with useful vision, however a number of potentially serious 
problems were subsequently recognized to be associated with EBRT –some 
being dry eye symptoms, radiation cataract and radiation retinopathy, facial 
cosmetic deformity and most importantly a number of malignant secondary 
neoplasm in the field of radiation13. With the use of radioactive plaque 
brachytherapy, laser photocoagulation and cryotherapy many problems 
associated with enucleation and EBRT were alleviated. 
In 1990’s a modality termed “Chemoreduction” evolved. Different 
chemotherapeutic regimens are being used. In 1990’s a combination of four 
drugs became the standard treatment for bigger tumours. Modalities frequently 
used for tumour consolidation include diode laser hyperthermia, cryotherapy 
and plaque brachytherapy. 
The familial nature of retinoblastoma was first reported in the early 19th 
century14.The most exciting current work on retinoblastoma has been on 
genetics and has had revolutionary implications for the understanding of the 
genetics of the malignant neoplasm in general. And with all the recent 
understanding about retinoblastoma and evolution of the new classification, use 
of chemotherapy with local therapy, the management of eyes with 
Retinoblastoma, should have become a multidisciplinary approach. This 
approach involving ophthalmologist with experience in ocular oncology, a 
radiation oncologist, a paediatric oncologist, a genetician, a neuroradiologist 
will enable us to have consistently excellent treatment outcomes in the future. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epidemiology  
INCIDENCE 
Retinoblastoma though is the most common primary intraocular 
malignancy of childhood, is a relatively rare form of child hood cancer.  
Earlier studies have shown the incidence of retinoblastoma ranging from 
1 in 1400 live births to 1 in 34,000 live birth depending on the country3  
It is estimated that around 350 new cases occur in United States every 
year. A more commonly used estimate is 11 cases per million children younger 
than 5 yrs or 1/18000 child birth1 
The incidence in India is reported to be 1:15000 live birth (Viswanath et al)  
RACE 
 There seems to be no racial predilection for retinoblastoma15. 
Retinoblastoma does appear to occur more commonly in poor patients world 
wide. Preliminary evidence suggest that the reason for this predilection is that 
the presence of HPV sequence in the RB tumour tissue may play a role in 
development of sporadic retinoblastoma16 
SEX 
Studies show that there appears to be no significant difference in the 
incidence of retinoblastoma by sex for children aged 0-14 yrs of age.  
AGE 
Retinoblastoma is diagnosed at an average of 18 months with 90% 
diagnosed before the patient reach 5 yrs of age. 
Children who are affected bilaterally are diagnosed at an average age of 
13 months, while patients with unilateral retinoblastoma are diagnosed at an 
average of 24 months of age17 
When a known family history of retinoblastoma exists, patients with 
bilateral retinoblastoma are diagnosed at an average of 11 months. 
Retinoblastoma is known to present with atypical symptoms in older 
patients studies show that clinical and histopathologic features were atypical in 
47% and 21% respectively in the retinoblastoma patients who presented after 
the age of 5yrs18  
Few cases of retinoblastoma in adults (aged 20 yrs and older) have been 
reported in the literature. Some have proposed that these lesions arise from a 
previously existing retinocytoma that underwent malignant transformation.   
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genetics in Pathogenesis of Retinoblastoma 
Retinoblastoma (Rb) occurs as a result of mutational inactivation of the 
Rb gene, which along with other genetic events allows the tumour to overcome 
the cellular safe guards against neoplastic transformation. 
Retinoblastoma occurs both in hereditary and non hereditary form. Even 
though less than 10% of new retinoblastoma patients have a positive family 
history, 30-40% of new patients will have the hereditary or germ line form of 
disease due to sporadic germline mutations. Hereditary retinoblastoma is 
characterised by autosomal dominat inheritance (phenotype), a high risk of 
multiple bilateral tumors, a life long predispositions to cancer throughout the 
body. Non hereditary retinoblastoma occurs in 60-70% of case and usually 
consists of unifocal retinal tumours and no increased risk of other cancers21.  
The retinoblastoma gene (Rb 1 gene) on chromosome 13q14 is the first 
human cancer suppressor gene to be completely characterized. The RB1 locus 
contains 27 exons ranging in size from 31 to 1,889 base pairs23. The 26 introns 
vary in size from 80 to 71,712 base pairs. The retinoblastoma gene product is a 
928 amino acid phosphoprotein whose normal function is to suppress cell 
growth. The activity of the protein is regulated by phosphorylation27.When the 
retinoblastoma protein is phosphorylated, it is inactive. With phosphorylation, it 
is able to repress DNA transcription and prevent cell division22 Two normal 
copies of the retinoblastoma gene are present in most human cells. Their 
function is to limit growth of the cell. Only one normal copy of the protein is 
needed to accomplish this function. The process of phosphorylation is 
controlled by a cell-cycle-dependent kinase23 .Retinoblastoma is unique in that 
all cases are thought to involve the same initiating genetic event –the biallelic 
mutational inactivation of the Rb gene.  
Knudson’s “two hit hypotheses” points out that retinoblastoma occur 
when both the copies of Rb gene are mutationally inactivated in the same 
developing retinoblast.  
In the hereditary form, one Rb mutation is already present in germline so 
only one subsequent mutation is needed. The “second hit” that inactivates the 
other copy of the Rb occurs frequently enough during retinal development that 
multiple tumours often occurs, because the inherited mutations are present 
through out the body, cancers are more likely to occur in other tissues, in 
contrast non hereditary Rb occurs only in the unlikely event that somatic 
mutations occur in both alleles of the Rb gene in the same retinoblast.  
Most RB1 germline mutations are minute deletional defects, 
duplications, or point mutations that are detectable by molecular (DNA) 
analysis24,25. Larger abnormalities are demonstrable by chromosome 
(cytogenetic) analysis or by a combination of both methods. Regarding the 
genetic events in the pathogenesis of retinoblastoma, the initiating genetic event 
as mentioned above is the bi allelic inactivation of the Rb gene. Several other 
chromosomal abnormalities are found with high frequency in retinoblastoma.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Growth Patterns, Presentation and Diagnosis of 
Retinoblastoma 
Retinoblastoma arises from a multipotent precursor cell that could 
develop into almost any type of inner or outer retinal cell. Intraocularly it 
exhibits a variety of growth patterns. The classic description of the GROWTH 
PATTERNS is as below. 
ENDOPHYTIC GROWTH  
Endophytic growth occurs when the tumor breaks through the internal 
limiting membrane and has an ophthalmic appearance of a white-to-yellow 
mass showing either no surface vessels or small irregular tumor vessels. This 
growth pattern typically is associated with vitreous seeding wherein small 
fragments of tissue become separated from the main tumor. In some instances, 
vitreous seeding may be extensive allowing tumor cells to be visible as spheroid 
masses floating in the vitreous and anterior chamber, simulating 
endophthalmitis or iridocyclitis, and obscuring the primary mass. Secondary 
deposits or seeding of tumor cells into other areas of the retina may be confused 
with multicentric tumors.  
EXOPHYTIC GROWTH  
Exophytic growth occurs in the subretinal space. This growth pattern 
often is associated with subretinal fluid accumulation and retinal detachment. 
The tumor cells may infiltrate through the Bruch membrane into the choroid 
and then invade either blood vessels or ciliary nerves or vessels. Retinal vessels 
are noted to increase in caliber and tortuosity as they overlie the mass.  
DIFFUSE INFILTRATING GROWTH  
This is a rare subtype comprising 1.5% of all retinoblastoma. It is 
characterized by a relatively flat infiltration of the retina by tumor cells but 
without a discrete tumor mass. The obvious white mass seen in typical 
retinoblastoma rarely occurs. It grows slowly compared with typical 
retinoblastoma.  
 
       PRESENTATION AND DIAGNOSIS OF RETINOBLASTOMA 
Retinoblastoma begins early, and most of the cases with a previous 
family history are detected on examination early in infancy. The average age at 
diagnosis in patients who have not been examined for positive family history is 
15 months for bilateral retinoblastoma and 24 months for unilateral 
retinoblastoma17. Most of the patients present by 3 yrs and presentation is rare 
after 5 years. Of all retinoblastoma 30% are bilateral and 70% unilateral. 
Because the tumour is not always bilaterally expressed in a patient who carries 
genetic abnormality, some unilateral retinoblastomas are familial. Thus 40% 
retinoblastomas are familial and 60% non familial. 
The modes of presentations are variable and must be understood for the 
timely diagnosis of the disease. 
  The most frequent mode of presentation is leukocoria 56%28. 
Strabismus is the next most frequent mode of presentation 24%, Defective 
vision in 8% cases and reinforces the need for a careful dilated fundus 
examination in all the patients with strabismus and defective vision on their 
initial visit to ophthalmologist26. Other modes of presentation are much less 
common27. Retinoblastoma can cause secondary changes in the eye, including 
glaucoma, retinal detachment, and inflammation secondary to tumor 
necrosis. Pseudouveitis, with a red eye and pain associated hypopyon and 
hyphaema, is a rare presentation. .Probably one mode of presentation causing 
the most difficulty in diagnosis being Orbital inflammation 26,27 mimicking 
orbital cellulitis, it may occurs in eyes with necrotic tumors and does not 
necessarily imply extraocular extension. Proptosis is a more common 
presenting symptom in most underdeveloped countries. The prognosis is clearly 
unfavourable for these patients. It is also rare for a patient to present with 
distant metastases. The tumour tends to metastasize late and usually presents 
some local ophthalmologic signs long before it metastasize. Finally in rare 
cases a pinealoblastoma, thought to be a retinoblastoma in pineal body, so 
called trilateral retinoblastoma28 may be the initial presentation.  
 
 
 
 
 
PROTOCOL FOR DIAGNOSIS IN CASE SUSPECTED AS 
RETINOBLASTOMA 
A flow chart has been proposed to be useful in the evaluation of a child 
in whom retinoblastoma is suspected29. The diagnostic work up in a child with 
suspected retinoblastoma has two purposes: 
1. To confirm and solidify the diagnosis of retinoblastoma and  
2. To confirm that the tumour is confined to the eye.  
The work up of a child with suspected retinoblastoma should begin with  
a careful extensive history taking including recording of patient information, 
chief complaints, history of presenting illness, past history, antenatal, natal, post 
natal , developmental, immunization, diet history and previous family history of 
eye tumours or enucleation or any malignancy in childhood. The history taking 
should be followed by physical examination by a paediatrician, a detailed 
ocular examination by an ophthalmologist. The infant should have a complete 
eye examination including determining the visual acuity and dilated fundus 
examination. If diagnosis of retinoblastoma is fairly certain, the patient should 
be promptly scheduled for an imaging study and a staging examination under 
anaesthesia.  
The most helpful diagnostic tools in order, are, CT, ultrasonography and 
if the CT is equivocal, MRI.     
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DIFFERENTIAL DIAGNOSIS 
The three most common causes for pseudoretinoblastoma were persistant 
hyperplastic primary vitreous (28%), coats disease (16%), and presumed ocular 
toxocariasis(16%). The differential diagnosis of retinoblastoma is mostly the 
differential diagnosis of leukokoria. Most of these can be ruled out on clinical 
grounds but some create difficulty in diagnosis. To make the process of 
diagnosis easier the following diseases can be categorized by presenting 
feature: 
Diseases presenting 
with leukocoria 
Diseases mimicking as 
exophytic tumor 
Diseases mimicking as 
endophytic tumor 
 Persistent 
hyperplastic primary 
vitreous 
 Congenital Cataract 
 Cicatricial 
retinopathy of  
      prematurity 
 Toxocariasis 
 Coloboma of choroid 
and optic disc 
 Uveitis 
 Pseudogliomas 
 Coats disease 
 Late stage vitreous 
hemorrhage 
 Retinal dysplasia  
 Medulloepitheliomas, 
 Tumors other than 
retinoblastoma and 
Retinal detachments 
 Coats disease 
 Toxocariasis 
 Choroiditis 
 Exudative retinitis 
 Choroidal 
hemangioma 
 Angiomatosis retinae 
 Retinal pigment 
epithelium 
proliferation 
 
 Retinal hamartomas 
 Astrocytomas 
 Myelinated nerve  
      fibers 
 Retinochoroiditis 
 Metastatic 
endophthalmitis 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic Imaging 
As soon as the ocular examination reveals classic findings of 
retinoblastoma imaging of the ocular structure, orbit and brain is warranted. 
The result of both the investigations-- the imaging studies and the staging 
examination under anesthesia together help in formulating the treatment plan. 
Imaging of the retinoblastoma patient has several intended functions: 
1) To confirm the clinical and ophthalmoscopic suspicion of the tumour 
2) To evaluate for retrobulbar spread 
3) To search for intracranial metastases 
4) To exclude a second intraocular tumour in both the affected eye and the 
contralateral eye. 
Ultrasonography (USG)-B Scan, Computerized tomography (CT) and, 
and Magnetic Resonance Imaging (MRI) are the most useful imaging 
techniques in evaluation of these lesions. Although MRI may be useful when it 
is difficult to distinguish between retinoblastoma and simulating lesions or 
when there is a question of optic nerve invasion, MRI is not as specific as CT 
because of its lack of sensitivity in detecting calcification30.  
MAGNETIC RESONANCE IMAGING (MRI) 
MRI may be beneficial in estimating the degree of differentiation of 
retinoblastomas but is not as specific as computerized tomography because of 
its lack of sensitivity in detecting calcification. 
Studies show that on T1-weighted images, the tumors usually appears 
slightly or moderately hyperintense than the surrounding normal vitreous but, 
on T2-weighted images, retinoblastoma tumors demonstrate very low 
intensity compared to vitreous. Calcification is more pronounced on T2 
sequences and appears as low signals in all sequences. Prominient enhancement 
is seen after Gd-DTPA administration. 
MRI also is useful in identifying any associated hemorrhagic or 
exudative retinal detachment. This is seen as a localized subretinal area of 
higher signal intensity compared to vitreous on both T1- and T2-weighted 
sequences. The MRI scan can demonstrate infiltrative spread along the 
intracanalicular and cisternal portions of the optic nerve, subarachnoid 
seeding, and involvement of the brain37 and is far superior to CT in this 
aspect. It is especially useful in determining extraocular spread after radiation 
and chemotherapy. 
CRANIAL AND ORBITAL COMPUTERIZED TOMOGRAPHY (CT) 
The value of CT in diagnosing retinoblastoma has been well 
documented.32 CT with its high sensitivity for calcification is the procedure of 
choice for diagnosis of calcification .The usual CT appearance of 
retinoblastoma is that of a calcified mass within the globe. The mass, which 
may be of any size, arises from the retina, but the borders may be ill defined 
making the retinal origin unclear. Calcification seen in 95% of these tumours 
may be large,small single or multiple. Enhancement is usually seen after 
contrast administration in CT scan. As Haik et al33 pointed out, calcification can 
occur in any of the retinoblastoma-simulating lesion where significant ocular 
disruption or phthisis is eveident, but this is dystrophic calcification usually 
deposited along the lines of normal structures.  
ULTRASONOGRAPHY (USG) 
The USG is the next best diagnostic confirmatory test. In 1973    
Coleman34 reported on the reliability of ultrasound in tumour diagnosis. The 
tumour and calcification can be diagnosed by ultra sonography; however the 
accuracy of Ultrasonography for this condition is only 80%35.  
USG may be helpful in distinguishing retinoblastomas from non 
neoplastic conditions36. Echographically retinoblastomas may have a smooth, 
dome shape, but more typically have a very irregular configuration. The 
internal reflectivity can vary according to the degree of calcification. Non 
calcified tumours demonstrate low to medium reflectivity, where as calcium 
produces extremely high internal reflectivity. The calcium may be quite dense 
and located throughout the lesion or confined to a small foci.. Demonstration 
of calcium is important in the diagnosis of retinoblastoma. These eyes are 
usually of normal size or larger. Consequently, their axial length measurement 
can often help in differentiating a case of retinoblastoma from other causes of 
leukocoria that presents with small globe. Echography is also important for 
monitoring the size of retinoblastomas that have been treated with radiation or 
alternative methods of therapy. In most instances these tumours that recur or 
continue to grow after treatment tend to exhibit low to medium internal 
reflectivity and do not show calcification.  
Studies show histopathology as being superior to echography in 
detecting Optic nervehead invasion,extra ocular extension and presence of 
calcification37,38 
The 3DUS allows for analysis of the acquired and stored volumes. 
Rotation and sectioning of this volume allows the discovery of new oblique and 
coronal views. The ability to retrospectively analyse the (scanned and stored) 
ocular volume will facilitate patient care, teaching, tumour volume analysis and 
tele medicine39. 
X-RAY STUDIES  
In areas of the world where ultrasonography and computerized 
tomography are not available, x-ray studies may be the only means of 
identifying intraocular calcium in patients with opaque media. 
FLUORESCEIN ANGIOGRAPHY 
Angiography is not necessary for making a diagnosis of retinoblastoma. 
Angiography may be of value if the diagnosis of recurrent retinoblastoma in a 
previously treated lesion is uncertain in which case an active retinoblastoma 
will leak, stain with fluorescein and accumulate the dye40 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examination under Anaesthesia, Lab Investigations 
and Histopathologic Features 
 
LAB INVESTIGATIONS  
Blood counts, electrolyte determination, Blood Haemoglobin values are 
useful to assess general condition of patient before subjecting to any procedure 
under general anaesthesia. 
The tests like routine bone marrow aspiration and biopsy as well as 
lumbar puncture are not necessary in new patients with retinoblastoma when 
there are no other signs that the tumour has spread outside the eye. However 
they may play a role if extraocular, metastatic or locally recurrent 
retinoblastoma is suspected.   
In cases in which there is clear evidence of tumour outside the eye, a full 
metastatic work up should be carried out and It should ideally include bone 
scan in addition to search for tumour cells in bone marrow and CSF.A whole 
body CT should be carried out and many times an MRI is helpful.  
Bone marrow analysis and CSF analysis are also done before 
administering the chemotherapy regimen. Hemoglobin estimation, Blood 
grouping, Blood counts, liver function tests, Kidney function tests, and Blood 
electrolytes help in assessing the patient’s general health before the patients are 
subjected to chemotherapy. A periodic repeat of these tests before 
administering each cycle in chemotherapy regime and after the completion of 
chemotherapy enables to find out the systemic adverse effects of drugs and alter 
the therapy or adjust drug dosage accordingly. 
Blood specimens should be taken not only from the patient but also from 
the parents and any siblings for DNA analysis, which could aid in genetic 
counseling. 
Assays of aqueous humor enzyme levels could offer useful information 
to patients with suspected retinoblastoma. Lactate dehydrogenase (LDH) is a 
glycolytic enzyme that uses glucose as an energy source. It is present in high 
concentrations within metabolically active cells. Normally, its concentration in 
serum and aqueous humor is low and the ratio of aqueous humor to serum LDH 
is less than 1.0 in patients with ocular disease other than retinoblastoma. 
However, aqueous humor for eyes with retinoblastoma exhibits increased LDH 
activity expressed as an aqueous humor/LDH ratio of greater than 1.0 
 
STAGING EXAMINATION UNDER ANAESTHESIA 
It is important to carry out a careful classification and staging 
examination under anesthesia before treatment. 
The examination should include evaluation of anterior segment, the iris, 
and the vitreous cavity. A good documentation of the findings with appropriate 
drawings should be made. Retinal drawings should be made of both the eyes 
with the location of lesion indicated. Wide angle retinal photography is 
extremely useful in the documentation of the eye findings. The height of each 
lesion can be estimated clinically .B scan Ultrasonography can be used to 
document the dimensions of the tumour and demonstrate calcification within 
the tumour. Comparison diagrams and follow up images are useful in assessing 
response to treatment and planning further treatment. 
 
HISTOPATHOLOGICAL FEATURES 
The classic histologic findings of retinoblastoma are Flexner-
Wintersteiner rosettes and less commonly fleurettes. A Homer-Wright rosette 
can be encountered, but they also are seen in other neuroblastic tumors.  
Considerable variability exists in the histologic features. Some 
neoplasms display marked necrosis and prominent foci of calcification. Few 
show areas of glial differentiation.  
Note: In an enucleated eye that is being prepared for gross examination 
and fixation for histopathologic examination, it is essential that adequate 
fixation is attained (fixation usually is complete within 48 h). Thorough fixation 
is especially important for eyes removed for retinoblastoma because the tumor 
is friable and may be spilled into the uvea or outside of the eye when the eye is 
sectioned, thereby confusing the assessment of the confinement of tumor to the 
interior of the eye (a feature that is important for the assessment of survival  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Staging of Retinoblastoma 
An ideal Classification and staging system of retinoblastoma should be 
(1).Simple and easy to use, (2).Reliable, (3).Capable of predicting the 
likelihood of successful treatment of new cases. 
The Essen Classification system did not receive widespread usage. The 
Reese-Ellsworth classification system was the most useful system when 
external beam radiation (EBR) was the standard of treatment for eye salvage. 
Now that chemotherapy has become a better option than radiation and 
more patients are subjected to chemotherapy schedules, this classification 
system is not as predictive of outcome and survival. A Linn Murphree and 
colleagues have developed (and are in the process of refining) a new 
classification system75, 76, 15 
REESE-ELLSWORTH CLASSIFICATION 
This system was originally developed in 1950s to predict the 
survivability of eye following EBRT. This was developed just as indirect 
ophthalmoscope was being introduced into clinical practice. Anterior lesions 
which can be easily treated now with cryotherapy or radioactive plaque, cause 
the eye to be classified as more advanced stage using the Reese Ellsworth 
classification. Also vitreous seeding of any amount places the eye in group 5b 
with the poorest prognosis. 
Nevertheless the Reese Ellsworth Classification has been used by most 
groups throughout the world for more than 30 yrs. 
Group 1- very favourable 
a) Solitary tumor, <4DD in size at or behind the equator 
b) Multiple tumors <4DD in size behind the equator 
Group 2- favourable 
a) Solitary tumor, 4-10 DD in size, at or behind the equator 
b) Multiple tumors 4-10DD in size behind the equator 
Group 3 - doubtful 
a) Any lesion anterior to the equator 
b) Solitary tumor, larger than 10DD in size, behind the equator 
Group 4 - unfavourable 
a) Multiple tumours, some larger than 10DD 
b) Any lesion extending to the ora serrata. 
Group 5 – very unfavourable 
a) Massive tumors involving >1/2 the retina 
b) Vitreous seeding 
 
NEWLY PROPOSED CLASSIFICATION FOR INTRAOCULAR 
RETINOBLASTOMA 15, 75, 76 
With the introduction of primary neoadjuvant chemotherapy 
(chemoreduction) as the initial management method, the Reese Ellsworth 
system fails to be helpful clinically. 
The following is a proposed system based on the likelihood of salvaging 
the eye when chemotherapy is used as the primary treatment of the intraocular 
malignancy. 
Group A 
Advantageous location & size disease. Avoids significant morbidity & 
vision loss. One or more intraretinal  tumours 3mm or less in greatest diameter; 
none touching the optic nerve or impinging on the foveal avascular zone. No 
vitreous seeding or subretinal fluid. 
Group B 
Brachytherapy-eligible disease. Solitary Rb outside zone 1 with a basal 
diameter no longer than10mm OR multiple, closely spaced, smaller tumors 
confined  to a single  retinal area no greater than 10mm in diameter. No diffuse 
vitreous seeding or significant RD  
Localized vitreous seeding is allowed no greater than 2 mm from the 
surface of the tumor. Significant RD is defined as an area of detachment equal 
to or greater than the retinal area occupied by the tumor. 
Extraretinal Rb defines the disease extending beyond the retina & vitreous 
Group C 
Confined disease of a size requiring chemotherapy. One or more 
intraretinal or endophytic tumors, none exceeding 15mm in greatest basal 
diameter. No local or diffuse vitreous seeding or significant RD. Small tumors 
(<3mm) touching the optic nerve or involving the fovea. 
Group D 
Dispersed, disseminated, or diffuse intraocular disease. Vitreous 
seeding or significant retinal detachment, or both, may be present. The total 
volume of the tumour does not exceed half the volume of the eye. No detectable 
extraretinal disease except for vitreous  involvement. Potential for useful vision.  
Group E-- for Enucleation 
Extraretinal retinoblastoma or the presence of intraocular tumor volume 
greater than half the volume of the eye. Primary enucleation recommended. 
Anterior segment disease, glaucoma, hyphema, total detachment with fixed 
retinal folds 
Group F 
Future risk  from containment failure. Neuroimaging or histological 
evidence of increased risk for metastatic disease (massive choroidal 
involvement and/or tumor in the optic nerve posterior to the lamina cribrosa). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment Modalities,  
Treatment Methods and Techniques 
Treatment approach for retinoblastoma has gradually changed over past 
five years  The treatment guidelines based on the proposed new classification is 
as follows: 
Group A 
Local treatment only; cryotherapy for peripheral disease, direct laser 
photocoagulation for posterior disease 
Group B 
Primary Brachytherapy (single site). If multiple brachytherapy sites are 
needed, downclassify to intraocular group C. If brachytherapy is not available 
treat like group C.   
Group C 
Three-drug chemoreduction (primary neoadjuvant chemotherapy) + local 
consolidation (crytherapy, laser, or plaque). Lens-sparing EBR consolidation 
for tumors that have minimal response to chemotherapy.   If age <1yr, consider 
plaque.  
Group D 
Four drug chemoreduction (primary neoadjuvant chemotherapy) with 
prechemotherapy cryodisruption + whole eye consolidation (whole eye EBR 
or intensified chemotherapy). Primary enucleation for unilateral group D 
 
 
Group E 
Primary enucleation in unilateral cases and in failure of conservative 
management in bilateral cases.  
Group F 
Adjuvant chemotherapy before and/or after enucleation. Add orbital 
radiation therapy if there is direct extension to the orbit or tumor extends to cut 
end of the optic nerve 
 
SPECIAL CASE MANANGEMENT: 
1.Retinoma: regular observation 41 
2.Unilateral Retinoblastoma: According to retinoblastoma study group Group 
D Unilateral cases Enucleation. and Group E Unilateral --Enucleation. 
Unilateral Group C –three or four drug chemotherapy42 
3. Bilateral Symmetric Retinoblastoma : 
a. Bilateral group A- Cryotherapy and laser photocoagulation if away 
from fovea,if close to fovea and optic disc down regulate to Group C and start 
chemoreduction 
b. Bilateral group B –rare presentation-Primary brachytherapy in each 
eye appropriate. If not available down regulate to Group C and start 
chemoreduction. 
c. Bilateral group C –more common presentation- Chemoreduction is 
appropriate. 
d. Bilateral group D four drug chemotherapy with Carboplatin, 
Etoposide, Vincristine and Cyclosporine A as primary treatment followed by 
local consolidation with cryo or laser. 
4. Bilateral Asymmetric Retinoblastoma 
If worse eye is group E enucleation is scheduled for that eye. 
If the group E eye also has optic nerve invasion and  the other is Group 
C or higher and requires chemotherapy ,enucleation for the Group E eye is 
delayed  until after at least three cycles of chemotherapy. This way the 
subsequent enucleation is uncomplicated and the orbital healing was good43  
In Group D disease in one eye and associated with Groups A to C in the 
second eye, if choice is made to salvage the group D eye, the treatment intensity 
should be aimed towards the Group D eye and local therapy to other eye should 
be delayed till the chemoreduction has its effect in the fellow eye.    
5 Vitreous Seeding 
 Vitreous seeding is a contraindication to photocoagulation and a relative 
contra indication to cryotherapy. 
It has been found that even with treatment with quadruple chemotherapy 
for diffuse vitreous seeding, massive recurrence occurred in 70% of eyes 
treated44.The presence of vitreous seeding in unilateral retinoblastoma is a 
reason to enucleate. In bilateral cases with vitreous seed, eye preservation 
therapy becomes essential. Recent studies have shown local therapy using intra 
vitreal injections of Melphalan combined with ocular hyperthermia can 
preserve about 50% of the eye balls with vitreous seeding45,46 
Another new approach is currently being investigated (Kishi Et al)-They 
attempted vitreous surgery with perfusion of anticancer drugs into vitreous to 
kill tumour cells during the procedure45 
6. Diffuse infiltrating retinoblastoma- Enucleation 
7. Retrolaminar Optic nerve involvement and choroidal involvement 
6-12 months of adjuvant chemotherapy is essential to prevent metastatic 
disease.  
8. Orbital Extension:  Systemic chemotherapy and orbital radiotherapy  
9. Metastases: Suspect metastases when advanced tumour size, and or anterior 
segment involved (Rubeosis iridis, Ectropion uvea, Tumour hypopyon) - 
Invasion of optic nerve past lamina27.High dose chemotherapy with 
Cyclophosphomide, Vincristine, Doxorubicicn and Palliative radiotherapy if 
symptomatic local disease is present.  
10.Trilateral retinoblastoma  - systemic and intrathecal chemotherapy and 
craniospinal EBRT47. Stephen Nelson et al showed the following therapy for 
trilateral retinoblastoma to be successful .Chemotherapy  initiated with intra 
venous administration of cyclophosphamide (750 mg/m2) on day 1. 
Then intrathecal chemotherapy is administered using guarded lumbar 
puncture and after extracting 1ml of Cerebro Spinal Fluid. The Intrathecal 
chemotherapy regimen which is given is Injection Cytarabine (14mg ),Inj 
Methotrexate (7mg), Inj Hydrocortisone (7mg ).Subsequent therapy,consisting 
of Cyclophosphamide and Vincristine administerd monthly and Methotrexate / 
Hydrocortisone / Cytarabine administered intrathecally at two month interval 
was given at the same dosage for 24 courses with resolution of the pineal 
enhancing mass. A custom made body cast can be used for delivering cranio 
spinal radiotherapy. 
 
TREATMENT METHODS AND TECHNIQUES 
1. CRYOTHERAPY 48,49 
It was first introduced by Lincoff in 1967 15 
Indication 49 
1. Small tumors confined to sensory retina, (less than 3-4 dd) not located 
at vitreous base, no vitreous seeds. 
2. If tumour is anterior to equator –transconjuctival approach. 
3. If tumour is posterior to equator –Through incision on conjuctiva. 
(curved cryo probe is used) 
Procedure(4) 
 Tumor visualized by I/O, elevated on the tip of the probe 
 Freeze at -90 degree C until tumor + surrounding retina incorporated in 
the iceball, rendering the tumor margins indistinct. 
 Thaw for 1 min before reapplying freeze  
 Repeat the same procedure in the same location twice more. Totally 
tumour treated three times per session for as long as 3-4min per freeze. 
 Two such cycles to be given at 1 month interval 
 End point –No viable or visible tumour remains, patient is left with a 
white chorioretinal scar.  
 Good effectivity with few less serious complications15 
Complications 
Transisent sub conjuctival edema, lid edema, and Vitreous hemorrhage 
and transisent Retinal detachments. 
 
2. LASER 48, 49, 50, 51,52 
Laser photocoagulation is typically not used with chemoreduction 
because it causes vascular coagulation and might minimize chemotherapy 
delivery to tumours. Thus use of laser coagulation in retinoblastoma has 
decreased in recent years53 
Indications54 
1. Children not treated with chemoreduction protocol 
2. Tumors < 4.5 mm base diameter/2.5mm thickness 
3. Tumour posterior to the equator, 
4. No vitreous seeds  
5. No SRF  
• Laser is delivered through indirect ophthalmoscope laser 
photocoagulation system. 
• Treatment directed to limit the spread of tumour and specifically 
coagulate all blood supply to tumour with argon or diode laser. 
• Special care not to treat tumour directly because it might induce rupture 
of internal limiting membrane and then seeding of tumour in vitreous cavity. 
Two to Three sessions at one month intervals necessary for complete 
regression15. Efficacy –With proper case selection 70% tumour control, 30% 
recurrence15 
Complications 
Transient serous retinal detachment, visually significant retinal vascular 
occlusion, Retinal traction, Retinal hole and Pre retinal fibrosis are the 
complications of the procedures.  
 
3. TRANSPUPILLARY THERMOTHERAPY 15 
It was first used by Lagendijik in 1982 was treatment of retinoblastoma. 
Mechanism of action:Laser beam directly aimed at tumour and thermal 
effect leads to direct apoptosis of tumour cells. 
Indication 
1. Viable tumour within the retina or subretinal space with less than 1mm 
overlying sub retinal fluid. 
2. Large tumours and vitreous seeding from the tumour are criteria for 
exclusion for this treatment. 
Procedure 
Thermal energy delivered from a 810 nm infra red ophthalmic laser with 
modification to laser hardware and software. 
Techniques 
1. Murphee et al55 – paediatric laser gonioscopy and an adapter on an aperating 
room microscope that delivers a Transpupillary 3.0mm spot of radiation. Power 
350-1500 mW and treated for one minute. 
2. Adaptor on indirect ophthalmoscope and a 20 D lens delivers a 
Transpupillary 1.6 mm spot of radiation, the power being 350-1500 mW and 
treatment performed in approximately one minute. 
3. Radiation delivered transconjuctivally via a diopexy probe.One minute of 
treatment using a hand held adaptor which delivers a 1mm spot of radiation, 
power being 500-1500mW.  
 
 
 
THERMOCHEMOTHERAPY (TCT) 49,15 
 Heat is synergistic with Carboplatin in the destruction of RB cells 
 Heating the tumour doubles the amount of Carboplatin bound to tumour 
DNA 
Procedure 
 One hour infusion of Carboplatin  18.7 mg / kg/ dose 
 Day 0 – Within 2 hours of completion of infusion –diode laser 
hyperthermia(810 nm infra red ophthalmic laser) 
 Day 8 – A new laser treatment not preceded by Carboplatin, with 
identical parameters  
 Three such cycles to be given at 28 day intervals 
 Spot size (depending on tumour size) 0.8 – 1.2 mm 
 Power (depending on tumour size)  
 <2 DD – 300 mW 
 3.4 DD – 450 mW 
 >4 DD     600 – 700 mW 
 Therapy considered adequate when there is whitening of the tumour and 
surrounding retina 
 A small amount of hemorrhage is acceptable. If significant edema 
noticed, laser energy is too much 
 End point- Tumour typically regress to flat pale scars that are less than 
2mm. 
Complications  
Focal iris atrophy (36%), focal paraxial lens opacity(24%), sector optic 
disc atrophy(24%), retinal traction(2%), optic disc edema(5%), retinal vascular 
occlusion(2%), serious retinal detachment(2%) and corneal edema (1%)15 
Follow up 
 Re-examine at 3 weeks – locally treat edge recurrence and residual small 
tumours 
 If tumour is in posterior pole laser photocoagulation is done. 
 If tumour is anterior to the equator cryotherapy is given. 
 Re-examine at 3 weekly intervals until 3 consecutive examinations show 
complete regression  
 Re-examine 3 monthly for at least 1 year 
Studies have shown that TTT alone is sufficient for tumours 1.5DD or 
smaller in diameter, and 64% tumours required only one session15   
 
4. BRACHYTHERAPY  
Episcleral brachytherapy was pioneered in 1933 by Henry Stallard 15 
Indications 
1. Reese Ellsorth IV a or less 
2. Tumours between 4 and 10 dd in size (Group B new classification) 
3. Large tumours >10dd and tumours involving macula are contra 
indications for this therapy. 
Procedure 
Under GA, in operating room, gold shields of  Iodine 125  (currently 
most used radioactive plaque) plaque designed to match the size of the lesion  is 
attached to the sclera over the tumour. 
Dose 
Primary Brachytherapy- 4000-4500 cGy  to the apex of the tumour at a 
rate of approximately 1,000 cGy per day. 
Chemotherapy Æ brachytherapy (20Gy) 
Plaque is by second operation 3-5 days later, depending on isotope and 
size of the tumour.(Ruthenium can also be used instead of iodine)  
Complications 
Side effects from brachytherapy for retinoblastoma are rare. 
Optic neuropathy and radiation retinopathy have been reported. Cataracts 
can occur after some years and often do not require surgery.  
 
5. ENUCLEATION 
First published in 1809 as a successful approach to treating intraocular 
retinoblastoma, enucleation continues to be main stay of treatment for patients 
with advanced intraocular disease. Patients are also considered for enucleation 
if they have failed all other forms of treatment, or if they have active tumour 
and cannot be followed56.Greater than 99% of patients with unilateral 
retinoblastoma without microscopic or macroscopic extraocular disease are 
cured by enucleation15. In all centers Enucleation for children is performed 
under GA  
Special precautions  
Avoid undue handling of muscles,avoid perforation of the globe. 
Avoid optic nerve snare to crush the nerve, use 9-10 ml of Xylocaine with 
adrenaline around the optic nerve before sectioning the nerve (to avoid bleeding 
and prevent micrometastases).  
Use minimally curved scissors and cut as long a section of the optic 
nerve as possible. 
Preferable to use orbital implants after enucleation for better cosmetic 
prosthesis 
Complications 
Most Common complication of enucleation are hemorrhage and 
infection. Hemorrhage is best controlled during surgery by firm digital and if 
necessary, thrombin soaked patties, Flo Seal, or Avitene (bovine collagen).Post 
operative ecchymosis usually subsides with use of a pressure patch and ice 
compresses. Infection is rare, those patients who develop recurrent infection of 
the socket are managed effectively by topical antibiotic therapy.  
Follow up 
Follow up done for determining other eye status and general status of the 
individual and to detect metastases. 
CT – scan taken – 6 monthly for 1year. 
EUA done 3 monthly for 18 months, yearly for 3 years 
 
6. EXTERNAL BEAM RADIOTHERAPY (EBRT) 
External Beam Radiotherapy has fallen out of favour in many centres 
now due to increased risk of development of additional non ocular cancers in 
survivors of germinal retinoblastoma. 
When EBRT is administered the dose prescribed to retinal target volume 
ranges from 4200 to 4600 cGy. The dose is administered in 180-200 cGy daily 
fractions, five times per week. 
Complications  
Other than the most dreaded long term complication of additional non 
ocular malignancies, patients experience skin erythema,radiation cataract,Facial 
and temporal bone hypoplasia.    
 
7. CHEMOREDUCTION PLUS SEQUENTIAL AGGRESSIVE LOCAL 
THERAPY (SALT)49,51,57,58 
Efforts to treat intraocular retinoblastoma with chemotherapy began with 
Kupfer in 1950s.Currently chemotherapy is an area of active clinical and basic 
science research and in past decade it has emerged as a important globe sparing 
treatment. 
Indications 
1. For patients who have visual potential in eyes containing tumour which are 
too large to treat with focal methods. Chemoreduction is used to shrink the 
tumour so that other focal methods can be administered after words. Group C & 
D tumours in new classification. 
2. As potential single modality eye preserving treatment for patients of any age 
with advanced unilateral or bilateral retinoblastoma. Permanent responses are 
rarely observed in these cases15 
3. As a palliative treatment for preventing or containing metastases in advanced 
diseases. 
The recommended chemotherapeutic regimen varies at different 
institutions. Regime preferred by Shields et al53 : Three drug regimen : 
Carboplatin, Vincristine And Etoposide  (CEV). The regimen is given for six 
consequtive cycles on a monthly basis. Focal therapy is included to individual 
tumours at cycle 2 or cycle 3 after adequate tumour reduction and subretinal 
fluid resolution are achieved. Focal therapy is then performed at each 
chemoreduction cycle upto cycle 6.It has been shown that ocular salvage has 
been improved with addition of chemoreduction to treatment regimen59. 
CEV protocol 
 Carboplatin Etoposide Vincristine 
Day 0  * * * 
Day 1 - * - 
Day 7 & 14 - - * 
 
Dosage for primary neoadjuvant chemotherapy, If Group C – 3 to 4 
cycles, If Group D – 7 to 9 cycles. 
Dosage of Drugs  
Vincristine 1.5 mg / m2 (0.05 mg / kg, 36 months), Etoposide 150 mg 
/m2 (5mg/kg <36 months), Carboplatin 560 mg/m2 (18.6 mg/kg <36months). 
Patients <10 kg dosed mg / kg. All infants <6 months of age at diagnosis 
decrease drug dosage by 25% first course and escalate to 100% if tolerated on 
second and subsequent courses. 6 such cycles are to be given monthly. 
Adjuvant therapy is to be started after cycle 2, EUA done to assess the 
response and residual tumor and the mode of therapy is selected to depend 
upon, tumor location, tumor size, small localized seed, and diffuse seeds. 
The various adjuvant therapy methods available are Photocoagulation, 
cryo for smaller tumours, Thermotherapy within 4 hours of the chemoreduction 
dose, EBRT for larger tumours > 12 mm base or diffuse seeds, Enucleation for 
extensively involved eyes (for unilateral group D) 
Follow Up 
Follow up advised to be for every month after each cycle of 
chemoreduction. Three monthly till 1 year – adjuvant treatment as required at 
the time of EUA. Six monthly thereafter  
Subconjuctival Carboplatin for retinoblastoma 
Local delivery of chemoreduction for intraocular retinoblastoma is 
aimed so that the eye benefits from treatment and systemic side effects avoided. 
Studies in animal models showing ability of carboplatin to penetrate sclera and 
reach vitreous cavity allowing for effective doses in eye with minimal toxicity 
shows subconjuctival carboplatin54 as most useful for treatment of vitreous 
seeds .Presently subconjuctival chemoreduction is combined with three agent 
intravenous chemoreduction protocol for children with advanced disease to 
achieve local chemotherapy boost in ocular region53 
POST TREATMENT FOLLOW UP 
The challenge to an ophthalmologist following patients treated with 
retinoblastoma is to be able to determine clinically the first sign of recurrent 
disease. The pattern of regression of the tumour varies, to a certain degree, with 
the treatment method.   
For local treatment methods, cryotherapy and photocoagulation, 
anything less than a flat pigmented scar is unacceptable. Regression pattern 
after radiation have been reviewed by Abramson et al60. 
Regression pattern after treatment 
Type 1 - calcification only 
Type 2 - fish flesh, transluscent appearance 
Type 3 - type1+type2  
Type 4 - flat white scleral scar 
Pretreatment volume of the tumour correlated with the long term 
regression patterns. 
The pattern of regression seen with the triple drug systemic 
chemotherapy for the treatment of group D disease generally shows type 3 
regression pattern. The lesion must generally be treated with another method or 
else the risk of recurrence at edge of previous lesion is relatively high. The 
same observation exists for Group C and larger tumours62 
Need for long term follow up has to be stressed for evaluating the 
recurrence of tumour in treated cases, to detect metastatic spread of disease, for 
visual and social rehabilitation and assessing long term survival of the patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim and Objectives 
AIM  
 To study the demographic features, clinical presentations, treatment 
modalities and outcomes in patients with retinoblastoma in a tertiary care 
centre.  
 
OBJECTIVES  
1. To study the demographic features of patients with retinoblastoma. 
2. To study the various modes of presentation of patients with retinoblastoma.  
3. To study the tumour characters in eyes with retinoblastoma. 
4. To study the different treatment modalities for retinoblastoma (including 
local ophthalmic therapy, chemotherapy, surgery) and outcomes of eyes with 
retinoblastoma, following treatment. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
 A Prospective and Descriptive study was carried out in newly diagnosed 
patients with intraocular retinoblastoma who were identified at the Aravind Eye 
Hospital, Madurai. India. 
 Patients eligible for consideration were all newly diagnosed cases of 
unilateral, bilateral or trilateral retinoblastoma who presented between January 
2004 and May 2005. All other cases of retinoblastoma previously treated 
elsewhere, or review patients who were subsequently subjected to 
chemotherapy during the follow up were excluded from the study.  
 The patients who presented for the first time were examined in the 
“Retinoblastoma Clinic” and were subjected to a detailed medical and 
ophthalmologic history taking including age, complaints at presentation, 
duration of symptom, antenatal, natal, postnatal, diet, immunization & family 
history including pedigree charting.  
 Assessment of visual acuity was done whenever possible either by 
ability to pick up cake decoration, ability to fix & follow light or visual acuity 
by SG chart (Scheridan Gardner Chart) in pre school and school going children.  
 This was followed by diffuse torch light examination, slit lamp 
examination whenever possible of anterior segment to look for hyphaema, 
hypopyon, pupillary reaction, secondary glaucoma and other signs of anterior 
segment involvement. Indirect ophthalmoscopy using 20D lens of the dilated 
fundus was done to diagnose tumour mass, retinal detachment, vitreous 
hemorrhage, vitreous seeding, signs of optic nerve head involvement. The 
diagnosis was confirmed using Ultrasound B Scan. In patients whom diagnosis 
could not be ascertained or to look for optic nerve infiltration & intracranial 
extent, a CT Scan Brain and Orbit (Plain and Contrast) was performed. In most 
of the patients, since they were children and could not cooperate for detailed 
examination of anterior and posterior segment in the outpatient department, a 
staging examination under anesthesia was performed and all anterior and 
posterior segment finding and character of the tumour were confirmed and 
noted.  The patients eyes were staged according to the “Newly proposed 
classification for Intraocular Retinoblastoma”. 
 General physical examination was done in all patients to assess general 
health detect a signs of metastatic disease.  
 Good general and genetic counseling was given for the family regarding 
the disease and the stage of the disease in their child, need for treatment, regular 
follow up in the treatment. Any interventional procedure was performed after a 
written informed consent from parent or guardian.  
 According to the staging of the eye with retinoblastoma, the eye was 
subjected to either or combination of local therapy, chemotherapy, 
radiotherapy, surgery. According to the location and size of the tumour Local 
therapy given was either or combination of cryotherapy, transpupillary 
thermotherapy, and laser barrage around the tumour. 
 The need for chemotherapy in individual cases was assessed in 
accordance to their stage of the eye after staging by New Classification of 
Retinoblastoma. In any patient requiring chemotherapy, a complete 
hematological examination, examination of peripheral smear, bone marrow 
examination, CSF analysis, Liver Function Test (LFT), USG abdomen and 
chest X-ray were done to determine the general condition of the patient, ability 
to withstand chemotherapy and detect distant metastases.  
 The liver function test and blood investigations were repeated before 
commencing each cycle of chemotherapy, to assess the adverse effect of 
chemotherapy and to determine the general body condition and fitness for that 
chemotherapy cycle. 
 Most of the cases subjected to chemotherapy received three cycles of 
triple drug regimen,(Vincristine 0.05mg/kg body weight as Intravenous (IV) in 
100ml Normal Saline(NS) on the first day, Etoposide 5mg/kg body weight in 
100 ml NS as IV infusion over 2 hrs on first day and same dose in 500ml RL on 
2nd day, Carboplatin 16.7mg/kg body weight in 500ml Ringer lactate as IV 
infusion over 2 hrs) on day 1 and day 5.On each day, premedication with BD 
dose of Inj.Emset, Inj.Ranitidine and Inj.decadran was given before giving 
chemotherapy drugs. Three such cycles were given at interval of one month. In 
two cases where regression of tumour was not observed with triple drug 
regimen a quadruple regimen including administration of Cyclosporine A was 
administered. Intrathecal chemotherapy in addition to systemic chemotherapy 
with VEC (6 cycles) was administered for one case of trilateral retinoblastoma 
and one case with suprachiasmatic extension of the tumour.   
 All cases unilateral, bilateral & trilateral retinoblastoma subjected to 
chemotherapy were advised every month follow up till the chemotherapy 
completion. EUA was performed during the chemotherapy cycles and during 
the follow up after chemotherapy to assess need for and deliver the local 
ophthalmic treatment and assess the response of tumour to treatment.  
 The final response of the retinoblastoma to treatment was noted at EUA 
performed one month following completion of planned chemotherapy cycles. 
Patient was then advised regular follow up every month for the next 3 months 
and every 3 months for next 6 months and ever 6 months for next one year.  
 The well being of the patients, the status of the normal eye or the treated 
existing eye is noticed in every follow up visits. Appropriate rehabilitation like 
cosmetic artificial shell for the enucleated eye was provided for the patient.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tables and Charts 
Table 1 
Patient Demographics 
S.No. Particulars No Percentage 
1. Patients 48  
2. Eyes 68  
3. 
Sex : 
        Male 
         Female 
 
26 
22 
 
54.17% 
45.83% 
4. 
Laterality: 
         Unilateral 
          Bilateral 
 
28 
20 
 
58.33% 
41.66% 
5. 
Mean age : 
          Unilateral  - 28 Months      (Range - 80 days to 72 Months) 
          Bilateral    - 22.31 Months (Range - 13 days to 96 Months) 
          Trilateral   - 24 Months 
 
Table 2 
Modes of 1st Presentation 
S.No. Particulars No Percentage 
1. Leukocoria 32 66.66% 
2. Secondary glaucoma 11 22.91% 
3. Squint  6 12.50% 
4. Proptosis 3 6.25% 
5. Vitreous hemorrhage 1 2.08% 
6. Hyphaema 1 2.08% 
7. Hypopyon 1 2.08% 
8. Defective vision 11 22.91% 
9. No specific complaints 3 6.25% 
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Percentage of Trilateral Cases in Bilateral Cases  
Mode of Presentation of Patients 
Table 3 
Eye Involved 
S.No. Particulars No Percentage 
1. 
Eye : 
        RE 
        LE 
 
33 
35 
 
48.53 
51.47 
2. 
Laterality : 
        Unilateral 
        Bilateral  
        Trilateral 
 
28 
20 
1 
 
58.33 
41.66 
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n =
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Table 4 
Staging 
According to the “Newly proposed classification of Intraocular retinoblastoma”. 
Unilateral cases 
S.No. Stage 
Total no. of 
eyes 
Subjected to 
Chemotherapy
No 
Chemotherapy 
Bilateral 
cases 
1. Group A 2 0 0 2 
2. Group B 2 1 0 1 
3. Group C 5 0 0 5 
4. Group D 9 1 2 6 
5. Group E 32 1 9 22 
6. Group F 18 14 0 4 
Total 68 17 11 40 
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Table 5 
Nature of Presentation of Tumour Mass 
S.No. Particulars No Percentage 
1. Single tumour mass 46 67.64% 
2. Multiple tumour mass 16 23.52% 
3. Retinal Detachment  26 38.23% 
4. Vitreous Hemorrhage  17 25.00% 
5. Vitreous seeding  11 16.17% 
6. Optic Nerve Infiltration  17 25.00% 
7. Orbital metastases  5 7.35% 
8. Choroidal metastases 7 10.29% 
9. Calcification 48 70.59% 
10. Retinal seeding  3 4.41% 
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Nature of Presentation of Tumour Mass 
Table 6 
Percentage of cases requiring chemotherapy 
S.No. Particulars 
Total no. of 
cases 
No subjected to 
Chemotherapy 
Percentage 
1. 
Total number of 
cases  
48 36 75.00% 
2. Unilateral  28 17 60.71% 
3. Bilateral  19 18 94.74% 
4. Trilateral  1 1 100.00% 
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Cases subjected to Chemotherapy-36 
Table 7 
Treatment Modalities 
S.No. Particulars No of Eyes Treated Percentage 
1. 
Enucleation  
              Unilateral  
              Bilateral  
45 
26 
21 
66.18% 
92.86% 
65.62% 
2. Exentration  2   2.94% 
3. Chemotherapy  36 75.00% 
4. EBRT 8 16.67% 
5. Focal Therapy 7 10.29% 
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Table 8 
Character of  Retinoblastoma which regressed following Chemotherapy  
S.No. New 
Classification 
Laser 
Treatment
Cryo 
therapy
TTT No. of 
Tumours
Additional 
Information 
1. B A A  1  
2. A A A  1 RB with 
Suprachiasmal 
extension 
EBRT given 
3. C A A  2 EBRT given 
4. D A A  4 EBRT given 
5. D A A  2  
6. D A A  2  
7. A A   3  
8. C A  A 2  
9. C    4 Only 
Chemotherapy
10. D    3 Only 
Chemotherapy
11. D A  A 4 Quadruple 
Therapy 
A - Administered  
Table 9 
Character of Tumour not responding to Chemotherapy  
S.No. New 
Classification 
Laser 
Treatment
Cryo TTT No. of 
Tumours
Additional 
features 
1. E G  G 1 RD, Vitreous 
Seeding (VS) 
2. D    1 No response 
to quadruple 
regiment  
3. E    1 Total RD  
4. E    1 Total RD, VS 
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Results 
 Our studies included 68 eyes of 48 patients with retinoblastoma. Out of 
these 48 patients, 26 were male and 22 were female (Male Female Ratio was 
1.18:1). 28 of them had Unilateral (58.33%), 20 of them had Bilateral (41.66%) 
and 1 out of the 20 bilateral cases had trilateral retinoblastoma at the time of 
presentation (5%). 
 The mean age at presentation of Retinoblastoma was 27.54 
months(Unilateral cases Mean 28.0 months(mo), Median 24 mo, and for 
bilateral cases mean 22.31 mo, median 21 mo).One patient of trilateral 
retinoblastoma was 2 yrs at presentation. The earliest age at presentation was 13 
days and highest age of presentation was 8 years. 89.58% of cases were 
diagnosed before 5 years of age and 27.08% before 1 year of age. 
 The mode of 1st presentation was leukocoria in 32 patient(66.66%), 
Secondary glaucoma in 11 (22.91%), Squint in 6(12.50%), Proptosis in 
3(6.25%), Vitreous hemorrhage in 1(2.08%), Hyphaema in 1(2.08%), 
Hypopyon in 1(2.08%), Defective vision in 11 patients(22.91%) and no specific 
complaints in 3 cases(6.25%). 
 Of the 68 eyes with retinoblastoma, 33 were right eye and 35 were left 
eye. According to the Newly proposed classification, the number of eyes 
belonging to Group A was 2, Group B was 2, Group C was 5, Group D was 9, 
Group E was 32 and Group F was 18. 
 46 eyes (67.64%) had single tumour mass, 16 eyes (23.52%) had 
multiple tumour mass, 26 eyes (38.23%) had significant retinal detachment, 17 
eyes (25.00%) had vitreous hemorrhage, 11 eyes (16.17%) had vitreous 
seeding, 17 eyes (25.00%) had optic nerve involvement, 5 eyes had orbital 
metastases, 7 eyes (10.29%) had choroidal metastases, (7.35%) 48 eyes (70.59) 
had calcification , 3 eyes (4.41%) had retinal seeding.  
Of the 28 unilateral cases, 28 eyes with retinoblastoma, 26 eyes were 
treated by enucleation, of these 2 eyes belonged to Group D, 10 eyes belonged 
to Group E and 14 eyes belonged to Group F category when classified on basis 
of Newly proposed classification of intraocular retinoblastoma. Of the 14 eyes 
belonging to Group F, all of them were subjected to Triple drug chemotherapy 
with Vincristine, Etoposide & carboplatin combination for preventing 
metastases. 
One eye belonging to Group D intraocular retinoblastoma was subjected 
to globe salvaging chemotherapy but patient did not follow up. 
One eye belonging to Group B was subjected to glove salvaging 
chemotherapy and the tumour showed complete regression at end of completion 
of chemotherapy and in subsequent follow up.  
One eye belonging to Group E was given S.C Carboplatin in to the 
socket following enucleation for preventing orbital metastases. 
One eye belonging to Group E category was given S.C carboplatin in to 
the socket following enucleation, but subsequently developed intraorbital mass 
which was advised excision biopsy but patient did not follow up.  
One eye belonging to Group F was given S.C carboplatin in to the socket 
following enucleation to prevent orbital metastases in addition to triple drug. 
 Of the 20 cases of bilateral retinoblastoma and one cases of trilateral 
retinoblastoma of the 20 bilateral cases, one eye with the higher grade of 
retinoblastoma was treated by enucleated. Of the enucleated eyes 16 eyes were 
Group E, One eye Group F. Two eyes belonging to Group F underwent lid 
spacing exentration.  
 In one case, in which the other eye was Group B retinoblastoma, the 
tumour was treated with only two episodes of TTT and showed complete 
regressed in the subsequent visit. 
 In remaining 18 bilateral cases all were subjected to chemotherapy for 
globe salvage of the other eye, 14 eyes followed up till the end of required 
number of chemotherapy cycles and out of which total 10 eyes showed 
complete regression of the tumor (71.42%). 5 eyes showed complete regression 
with chemotherapy and local therapy {Group D 2 cases, Group A 2 case, Group 
C 1 case}. 
2 eyes {both eyes were Group C according to new classification} 
showed complete regression with only 3 drug chemotherapy. 
2 eyes showed complete regression with 3 drug chemotherapy and 
EBRT + local therapy {Group C one eye in which other eye had shown optic 
nerve infiltration Group F, the other eye was group D}    
1 eye belonging to Group D regressed with quadruple therapy + Local 
TTT. 
4 eyes did not show regression of the tumour mass –Three of them were 
Group E and 1 Group D which failed to regress despite use of Quadruple 
chemotherapy regimen.                                                                                                                        
4 eyes did not follow up – 3 were Group E, 1 was Group D. 
            In one bilateral case, an 8 year old female child with suprachiasmal 
spread of the retinoblastoma, the child underwent lid sparing exentration of 
Right eye and it was treated with Intrathecal Chemotherapy, triple drug 
systemic chemotherapy and EBRT for orbit & craniospinal irradiation as per 
the regimen proposed by Stephen Nelson et al. The patient showed complete 
regression of Group A tumour in the other eye and the regression of supra sellar 
tumour. But patient subsequently after 5 month of completion of Chemotherapy 
developed knee pain and patient was suspected to have developed Osteogenic 
Sarcoma and referred to higher centre for management. Patient failed to follow 
up after that 
 One patient with trilateral retinoblastoma was given intrathecal 
Chemotherapy, and one cycle of triple drug regimen, but failed to follow up 
after the first cycle. 
Over all 26 Unilateral, 18 eyes in bilateral retinoblastoma & 1 eye in 
trilateral retinoblastoma required Enucleation. Overall 45 eyes - 66.18% of eyes 
required treatment by enucleation.  
• 92.85% of unilateral cases required enucleation. 
• 2/20 bilateral case required exentration (10%). 
1 out of 20 bilateral cases were trilateral cases (5%). 
36 out of 48 patients - 75% needed chemotherapy  
11 out of 15 eyes with tumour subjected to appropriate systemic 
chemotherapy for globe salvage regressed completely. (73.33%) 
8 Cases needed EBRT for treatment of tumour (16.66%) 
 7 eyes received focal therapy - 10.29% 
Overall follow up rate among patients with retinoblastoma subjected to 
chemotherapy 69.44% (11 patients failed to follow up - 5 bilateral cases, 6 
unilateral cases). 
Overall follow Up rate for acceptance of treatment in patients with 
retinoblastoma 72.91% (13 patients did not accept treatment).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Demographic features  
In our study The average age at presentation was 27.54 months (Unilateral 
cases – 28 months, bilateral cases 22.31 months). The median age at 
presentation was 24 months (24 months in unilateral cases and 21 months in 
bilateral cases). The minimum age at presentation was thirteen days and 
maximum age was 8 years. 89.58% were diagnosed below 5 years of age and 
27.08% before age of 1 year 58.33% had unilateral diseases & 41.67% had 
bilateral disease, 10%of the bilateral cases had bilateral disease. Male female 
ratio was 1.18:1.    
In Tamboli series3 95% of cases of Retinoblastoma were diagnosed 
before age of 5 years and 40% diagnosed before 1 year. 
 Shields et al62 in a review of 1,196 eyes with Retinoblastoma which 
presented between 1974-2001, reports, median age in months (Mean, Range) as 
15(22,1-550), male to female ratio as 1.04:1, 53% of cases being unilateral, 
47% being bilateral, 51% right eyes and 49% left eye, 
  S.P.Dhir et al63 in 1980 in analysis of 47 cases of Retinoblastoma which 
presented between 1972 and 1976, reported minimum age at presentation 6 
months and maximum age 7 years. The average age at presentation was 48 
months, male female ratio was 1:1.474, 60% of the eyes were unilateral and 
40% were bilateral. 
 Sahu S et al63 in a study in 1998 about Clinical and Epidemiological 
character of Retinoblastoma reported the median age at presentation as 42 
months (3.5years) (42 months for unilateral and 12 months for bilateral), male 
female ratio as 1.4 : 1, 74.5% of eyes were advanced stage  diseases (Reese – 
Ellsworth Grade IV and V).  
The age at presentation in our study in slightly more (9 months) higher 
when compared to studies from western literature, but much less (18-21 months 
lesser than studies from India published before). The number of cases which 
presented to us before 1 year of age in lesser than in western studies 
 
Clinical presentation 
In our study the classification of the eyes with retinoblastoma was done 
only according to the Newly proposed classification for retinoblastoma.  
Reese-Ellsworth classification system for intraocular retinoblastoma was 
designed to help predict which eyes would most likely be salvaged after 
primary external beam radiotherapy. Anterior lesions, which can now be easily 
recognized and treated with cryotherapy or radio active plaque, cause the eye to 
be classified in a more advanced stage when using Reese-Ellsworth 
classification. Also local vitreous seeding of any amount places the eye in 
Group 5b with poorest prognosis. With combination of chemoreduction and 
local therapy, vitreous seeding, a frequent finding of large tumours is 
successfully treated in almost 75% of cases.  Studies have shown erratic 
correlation of the Reese-Ellsworth classification with treatment success 
following chemoreduction74 and more than 10 yrs ago itself Bob-Ellsworth 
discussed the fact that Reese –Ellsworth was out of date and should be 
revised.(R.M.Ellsworth, personal communication , Nyon, Switzerland, 1987). 
Since chemoreduction and all local therapy for treatment of 
retinoblastoma were available in our set up and eyes could be mananged with 
appropriate combination of methods available, eyes with tumour were classified 
on basis of New classification.  
In our study, Leukocoria (66.66%) was the most common mode of 
presentation, followed by defective vision (22.91%), secondary glaucoma 
(22.91%), squint (12.50%) and proptosis in (6.25%). According to New 
classification 86.76% of eyes in our study, had advanced stage disease (Group 
D to Group F). 
In study by SP Dhir et al63 in India (1980) of 47 eyes with 
Retinoblastoma, proptosis was the most common mode of presentation 68% 
followed by 17% being white reflex and squint 6.1%.  
In western literature, almost all series of retinoblastoma, Leucokoria 
has been the most common presenting sign, strabismus the next most frequent 
mode of presentation71,72 and other presentations as with glaucoma, defective 
vision, orbital cellulites etc as less common presentation73.                         
Barret G.Haik et al73, in an analysis of 250 cases 11% had positive family 
history, 56% had white reflex, 20% had strabismus, 7% had glaucoma, Poor 
Vision in 5 %, no complaints in 3%, orbital cellulites in 3%, Hyphaema in 1%. 
Most common mode of presentation in our study is leukocoria similar to 
those reported in western literature, percentage presenting with defective vision 
is second highest and is higher than reported in western literature. Percentage 
presenting with strabismus is markedly lower than in western reports. 
Percentage of glaucoma, proptosis, and hyphema is higher in our study. 
When compared to previous Indian study in 1980 the presentation as 
proptosis has definitely decreased, indicating that compared to a decade before, 
the disease is being diagnosed at an earlier stage in India. The percentage of 
eyes presenting in advanced stage of disease in our study is still slightly higher 
than that in the western population. This data in our study indicates that in 
India, probably due to increasing literacy among population making them avail 
medical care earlier, higher degree of suspicion in medical population to look 
for the disease, and availability of modalities to diagnose and treat diseases 
earlier, efficiently and appropriately, the disease is being diagnosed earlier than 
it was a decade before, and further improvement in above said factors and 
institution of screening for Retinoblastoma will help us diagnose and treat 
Retinoblastoma in par with the western world. 
 
Treatment modalities for Retinoblastoma : 
Abramson, MD et al15 and Carol C.Shields MD et al65 have described 
the various treatment modalities available for Retinoblastoma including the 
recent and emerging developments in management. The modalities of treatment 
being, enucleation for retinoblastoma that fills most of the eyes and especially 
when tumour invasion into the optic nerve or choroids is suspected. External 
beam radiotherapy as an important method of treating less advanced 
retinoblastoma especially when there is disease vitreous or subretinal seeding 
plaque radiotherapy, for small and medium sized RB, Cryotherapy & 
photocoagulation as providing good control of selected small tumour. 
Thermotherapy, the newest focal treatment method fro retinoblastoma and the 
combination of thermotherapy and chemotherapy providing satisfactory tumour 
control & the need for further study & follow up to determine fully the safety & 
applicability of periocular administration of carboplatin & other potential 
agents.  
In our study, therapy was instituted as per individual case requirement. 
Unilateral cases 92.5% were in advanced stage and so were enucleated. We had 
the diseased eyes enucleated because studies70 have shown chemo reduction 
combined with local ophthalmic therapy less effective in RE group 4 & more so 
in RE group 5 with or without vitreous seeds. In bilateral cases 100% of them 
presented with at least one eye or in few cases both stage disease (New 
classification D to F).  
 In bilateral cases, one eye with advanced disease stage was enucleated & 
in one case exentrated, for the previous reports mentioning of poor tumour 
response in them & also in a view to decrease the tumour load when the salvage 
of patient’s other eye was attempted by chemo reduction and local ophthalmic 
therapy. Histopathlogical examination of the enucleated eye enabled us having 
a definite histopathological diagnosis of retinoblastoma and to know the status 
of optic nerve and choroids since infiltration into either warrants a more 
aggressive & compulsory systems therapy. By decreasing the tumour load, the 
total number of cycles of chemotherapy administered could be decreased & 
thus adverse effect of chemotherapy can be decreased. We thus after 
enucleation of the eye with advanced disease, administered only 3 drug regimen 
(VEC) for only 3 cycles in majority of cases in a view that Indian children 
general health might not tolerate a higher cumulative dose, and in minimum 3 
months follow up of tumour which regressed there were no recurrence. External 
beam radiotherapy was administered in only 8 cases as an adjunctive method 
for chemoreduction.. 
 Most studies of chemoreduction for retinoblastoma since 1996 have 
utilized Vincristine, carboplatin Etoposide or Teniposide66,67,68,69,70. The choice 
of agents as well as number & frequency of cycles had been varying currently 
at different institution update. 
 In a pilot study of 20 patients, Shields et al69 found that two cycles of 
VEC was sufficient to promote regression in all 54 tumours studied in 31 eyes. 
Further follow up revealed that six cycles of chemotherapy decreased the 
vitreous seed recurrences.  
 Debra L Fried man, Bruce Himelstern, Carol L shields et al71 in a 
study of 75 eyes of 47 children, patients were treated with a six cycle protocol 
of VEC regimen along with local chemotherapy methods given during monthly 
or bimonthly ophthalmic regimen. Under GA and they reported that used of 
chemoreduction with local ophthalmic patients with eyes in RE group 1 to 3 
and that the therapy was less effective for group 4 & group 5 patients. 
In our study only 15 eyes of 15 patients were available for assessing the 
response of retinoblastoma to chemoreduction & local ophthalmic since 45 eyes 
were enucleated (26 unilateral, 17 eyes of bilateral cases), 2 eyes underwent 
exentration & 5 eyes could not be assessed since the 5 patients did not follow 
up, one eye showed total tumour regression with cryotherapy and laser barrage. 
 Of the 15 eyes which received total course of chemotherapy and local 
therapy with or without EBRT as planned – 11 eyes showed total regression of 
tumour (73.33%) & follow up of minimum 3months and maximum 15 months 
showed no recurrence. One of these patient required quadruple regimen 
including Cylosporin A & 3 patient received EBRT in addition to 
chemoreduction & local therapy. One patient of bilateral retinoblastoma with 
suprachiasmal extension of the tumour treated with one dose of intrathecal 
chemotherapy and 6 cycles of VEC regimen, showed complete regression of the 
Group A tumour in the other eye and the suprasellar tumour. 3 patient received 
EBRT in addition to chemoreduction & local therapy. In 2 patients tumour 
regressed only with chemotherapy. None of these eyes which showed 
regression had Retinal detachment, Vitreous seeding, Vitreous Hemorrhage at 
presentation. 
In eyes subjected to chemoreduction and local of ophthalmic therapy, 
enucleation could thus be avoided in 73.33% of cases, and both enucleation & 
EBRT could be avoided in 53.33% of cases subjected to Chemoreduction and 
local opthalmic therapy. 
The 3 eyes which did not show regression had Retinal detachment, 2 had 
vitreous seeding & one eye did not respond in spite of quadruple regimen. 
Overall follow up among patients subjected to chemotherapy is 69.44%. 
Over all acceptance to treatment was 72.91%. 
 In our study, the initial experience of administering chemoreduction and 
adjuvant local ophthalmic therapy for treatment of retinoblastoma, showed 
good regression of tumour in 73.33% of cases and is an encouraging result. 
Since most of the tumour presented in advanced stages Group E and Group F 
and needed enucleation not many eyes were available to assess response of the 
tumour subjected to chemoreduction and adjuvant therapy. 
 There were no adverse effect of chemotherapy in our study and drugs 
could be safely administered. 
 Our study was limited by time, a long term follow up and recruitment of 
more eyes for treatment will enable us analyse and compare our results 
following therapy to other major studies from western literature which have 
assessed response to chemotherapy. This will help us in formulating and 
standardizing a protocol for treatment of retinoblastoma in an Indian tertiary 
care set up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions  
1. Our study showed presenting age to  be  slightly higher than in western 
literature(The mean age at presentation was 27.54 months (Unilateral 
cases – 28 months, Bilateral cases 22.31 months).  
2. In our study the number of cases that presented to us before the age of 1 
year was lesser when compared to the western literature. (27.08% 
diagnosed before age of 1 year).  
3. Male Female Ratio (1.18:1), Percentage of unilateral (58.33%) and 
bilateral retinoblastoma (41.67%), in our study was similar to previous 
reports from western world.  
4. Percentage of trilateral retinoblastoma (5%) among the bilateral ones in 
our study was similar to previous reports.  
5. Leucokoria(66.66%) was the commonest mode of presentation in our 
study similar to other studies. But mode of presentation with defective 
vision(22.91%), glaucoma(22.91%), proptosis(6.25%) were higher in 
our study compared to western literature. Presentation as strabismus 
(12.50%) was much lesser in our study.  
6. Percentage of cases (86.76%) presenting in advanced stage of disease 
were higher.  
7. The response to attempt to salvage eyes using chemoreduction & local 
therapy with three cycle VEC regimen seems promising (regression of 
tumour in 73.33%). Even group D tumours have shown regression 
completely after chemoreduction, local therapy and EBRT (EBRT was 
required is one out of 5 Group D cases which showed regression of 
tumour).  
8. Retinal detachment, vitreous seedings and vitreous hemorrhage at 
presentation could be taken as indicators for poor prognosis for tumour 
regression.  
9. A long term follow up is necessary to assess the long term survival of 
these patients, and also to diagnose the recurrence of tumour if any in 
these patients and to decide if more number of cycles of chemotherapy 
has to be administered. 
10. Follow up of patients and acceptance to treatment is low (below 75%) 
and should be improved.  
11. Emphasis on early screening & diagnosis is advised to enhance 
prognosis and quality of life in these patients.  
12. All the treatment modalities for retinoblastoma available in western 
countries can be made available in tertiary eye care centre in India. 
Chemotherapy including triple regimen (VEC), Quadruple regimen in 
resistant tumour, Intrathecal chemotherapy for trilateral retinoblastoma 
can be safely administered in a tertiary eye care centre & response can be 
assessed. With the early diagnosis, application of chemo reduction & 
local therapy the percentage of Enucleation and EBRT, morbidity and 
mortality of patients can be decreased.  
13. There is a necessity to create a national registry to understand the actual 
impact of retinoblastoma in our country, treatment modalities should be 
standardized so that every centre can offer best available treatment at 
lower cost for patient. 
14.  A multi centered clinical study in India is necessary to evaluate clinical 
presentation, response of chemoreduction, local therapy in 
retinoblastoma in India.  
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RETINOBLASTOMA-Prospective analysis - Detailed Case Sheet 
 
 
1. Name: (kindly take clinical photo,Gross Eye  
2. MR NO: specimen photo,HPE slide photo,Recording of 
 fundus picture during EUA every visit)     
3. Date of first visit   -------------------- 
4. .Age ____________( mention if in days/months / yrs)            
5. Date of birth _____________(mm/dd/yy) 
6. Sex  
7.Address: 
 
 
8.Presenting illness (kindly encircle the appropriate entity ) 
Symptoms  Right eye  Left eye 
1.White reflex  Y N  Y N 
2.Duration of white reflex in  
   days and months   ___d/__m    __d/__m 
3.Squinting  Y N  Y N 
4.Pain  Y N  Y N 
5.Redness  Y N  Y N 
6.Swelling of  eye  Y N  Y N 
7.Dimness of vision  Y N  Y N 
8.Others(please specify) 
   esp Trauma,pet animals 
 
 
9.Past History: 
1.Similar illness in same eye  Y   N 
2.Similar illness in the other eye  Y   N 
3.Treatment offered elsewhere /AEH  Y   N 
    
(if yes specify what    Right eye  left eye 
 1.Laser   Y N  Y N 
 2.Cryo   Y N  Y N 
 3.EBRT/plaque   Y N  Y N 
 4.Chemotherapy   Y N  Y N 
 5.Enucleation   Y N  Y N 
4.any other major hospitalization requiring illness in the past(specify)    . 
  
 
10.Antenatal  History: 
 
1.Full term delivery  Y N 
2.Normal delivery / caesarean section 
3.H/o fever in mother during gestation (specify what and which month and treatment  
if any)  __________________________________ 
4.other drug use in gestation,radiation if any 
 
 
 
 
11.Family history    
(if yes specify which eye and which member: mother,father,sibling,distant relative)  
of squinting,white reflex,proptosis,death due to ocular cause,enucleation, 
diagnosed ocular tumour,retinoblastoma,other cancers 
 (Family tree) Ο----  
 
EXAMINATION 
12.General systemic examination 
1.obvious congenital anomaly 
2.lymphadenopathy (region if present ---preauricular ,post auricular, submandibular 
deepcervical ,.any other group(specify) 
3.hepatospleenomegaly Y N 
4.skeletal system 
5.CVS 
6.RS 
 
13.Ocular examination Right eye  Left eye 
 
1.vision  ---------   ------- 
2.leukokoria   Y N  Y N 
3.proptosis  Y N  Y N 
4.orbital cellulites  Y N  Y N 
5.cornea cloudy  Y N  Y N 
6.Anterior chamber 
 a.hyphaema y  n  y n 
 b.hypopyon y  n  y n 
 c.exudates y  n  y n 
 d.Depth 
 (mention shallow or deep) 
7.Iris a. colour pattern(normal/heterochromia) ------  ----- 
         b.Neovascularisation.   ------  ----- 
8.lens   ----------  ------------ 
9.Extra ocular movements 
{F-full;R-restricted)   -------   -------- 
10.Pupils(specify)  Ectropion uvea y  n  y n    
  size(mm) -----   ------- 
 shape -----   ------- 
 reaction-direct -----   ------- 
                indirect -----   ------- 
 
13.Fundus Findings:Kindly mention 
    glow,posterior pole as seen in direct opthalmoscope,I/O whenever possible, 
    Retinal detachment if any.   
 
 
 
 
 
 
 
 
 
 
14.Fundus                            Examination under anesthesia 
   RE  LE 
a.Corneal diameter in mm -----------        ----------- 
b.IOP (by schiotz in mmhg) -----------        -----------  
13B.FUNDUS PICTURE (examination under anesthesia) 
 
 RE     LE 
 
       
   
 
 
 
 
     
c.Tumour mass   y/n  y/n 
b.Number of tumours seen 
. 
c.Type of mass 
 1.endophytic  y/n  y/n 
 2.exophytic  y/n  y/n 
 
d.Tumour overlying  optic nerve head  y/n  y/n 
e.Mass overlying Macula   y/n  y/n 
f.Vitreous seeding   y/n  y/n 
g.Vitreous hemorrhage  y/n  y/n 
h.Retinal detachment    
(Mention if significant or not )  y/n  y/n  
i.no view   y/n  y/n 
 
14. 
 
Radiolo
gical 
methods 
Axia  
Length 
Of 
globe 
in mm 
Type 
of 
growth 
(endo-
phytic/ 
Exo- 
phytic) 
Dia- 
meters 
Of mass 
 
  
 
In mms 
Reflectivity 
From inside 
globe 
indicating 
Calcificatio
n 
Yes/no %of 
tumour 
occupied 
Optic 
Nerve
& 
Nerve 
head 
VH RD VS 
1.USG--
RE 
         
2.USG--
LE 
         
VH-Vitreous hemorrhage,VS-Vitreous seeding,RD-Retinal detachment(specify type,extent) 
 
15. CT findings(if done)-axial length of globe,dimensions,calcification,optic nerve involvement,  
      brain mets) 
16. MRI findings (if done) 
 
 
 
 
 
17.Structures/features in CT   MRI 
 
1.optic chiasma 
2.pituitary fossa 
3.pineal gland 
4.Brain Parenchyma 
 
18.Provisional diagnosis with staging according to “New classification for intraocular  
Retinoblastoma “ 
19.Management:     RE   LE 
 
1.Enucleation 
2.Enucleation status(mention appropriate choices) 
a.Primary    b.Pre chemotherapy 
 c.Post chemotherapy d.Pre radiotherapy  
ePost radiotherapy 
3.Chemotherapy  
4.Indication for chemotherapy 
a.Vision salvage,b.Globe salvage 
c.ONH invasion,choroidal invasion      
(life saving-To contain metastasis) 
d.Metastatic RB-Palliative) 
5.Total  no of cycles given 
(till end of chemotherapy or last follow up date) 
6.Regimen used (triple/Quadrple) 
7.Total number of follow up 
8.Total number of additional local therapy given 
9.Tumour response 
A.(regression pattern) –which cycle  
B.Degree of regression 
10.Adverse effect of chemotherapy 
11.Post chemotherapy enucleation or EBRT 
12.Local recurrance or distant metastases 
 
20.Histopathology reports in enucleated eye 
 
GROSS: 
 1.Type of Growth endophytic/exophytic    
2.calcification yes/no  extent in terms of tumour size ---- 
3.Necrosis. yes/no  
 
MICROSCOPIC 
 1.Differentiation Well differentiated/undifferentiated 
 2.Choroidal invasion(kindly Grade if present) ---yes/no 
 3.Optic nerve infiltration yes/no 
 
 
 
 
 
21.B.Details of Chemotherapy: 
1.MRD NO:------------ 2.Age in months-----  3.Weight in kg------------ 
 
Items Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 
1.Pre chemotherapy 
 investigations 
TC,DC,ESR, 
Hb,Blood GROUP, 
USG Abdomen, 
CSF analysis, 
SGPT,SGOT,ALP, 
other +report if any. 
      
2.Carboplatin       
3.Vincristine       
4.Etoposide                               
5.Cyclosprorine A       
6.a.Tumour response 
b.Additional local 
treatment given 
c.follow up adviced 
d.adverse effects 
      
 
 
 
 
Additional Points if  Any: 
ANTI –CANCER MEDICATIONS 
Cyclosporin A  
 Cyclic polypeptide that acts as an immunosuppressant drug.It inhibits 
early cellular response to antigenic and regulatory stimuli (cyclophilins), 
mainly in helper T – cells 
 Onset of action : within 12 hours 
 Duration of action : upto 72 hrs 
Adverse effects 
 Nephrotoxicity, Hypertension, Tremor, Seizures 
 Increased incidence of infection, Gingival hyperplasia, Hirsutism 
 Flushing, Paraesthesias, Tinnitus, Headache 
 Gynaecosmastia, conjunctivitis 
Dose: 
 33 mg / kg/ dose intravenous over 3 hours—5-6 mg/kg  
Preparations: 
 Immusol (Dabur) 50 ml solution – 100 mg/ml Rs 3860  
 Sandimmune (Novartis) 1 ml – amp – 250 mg / ml Rs 123 
Carboplatin 
 A platinum coordination compound, produces predominantly interstrand 
DNA cross links causing equivalent lesions and biological 
effects.inhibits both DNA and RNA synthesis.Binds to proteins an 
dother compounds containing SH group.Cytotoxicity can occur at any 
stage of cell cyclebut cell is most vulnerable to action of these drugs in 
G1 and S phase. 
 Duration of action : Terminal half life 5 days 
Adverse effects :  
– Vomiting, Thrombocytopenia, Raised alkaline phosphatase, 
Abnormally decreased serum electrolyte, Pain, Asthenia 
 
 Aluminium and mannitol can react with carboplatin. So do not use needs 
or I.V sets containing aluminium parts that my come in contact with 
carboplatin 
Dose : 560 mg / m2/ dose or 18.7 mg / kg/dose intravenous over 1 hour in  
100 ml normal saline 
Preparation: 
– Neocarb Inj. (biological E) 45 ml vial – 450 mg Rs1800 
– Carbotinal inj (Neon) 45 ml vial – 450 mg Rs 2650 
Etoposide 
 It inhibits DNA synthesis and is most active against cells in the late S 
and G2 phases of the cell cycle. Binding of drugs to enzyme-DNA 
complex results in persistence of transient cleavable form of complex 
and, thus, renders it susceptible to irreversible double strand breaks. 
 Duration of action : 3-19 hours 
Dose – 150 mg/m2/dose or 5 mg/kg/dose intravenous over one hour in 100 ml  
normal saline 
Adverse effects 
 Nausea,Vomiting,Diarrhoea 
 Allergic reactionsFever 
 Hypotension 
 Bone marrow depression, Peripheral neuropathy 
 Jaundice,Bronchospasm,Bleding and myelo suppression. 
 Preparations : Etosid (Cipla) 5 ml vial – 100 mg / 5 ml Rs 190  
 Fytosid (Dubar) 5 ml vial 100 mg / 5 ml Rs 193 
 
Vincristine 
 Avince alkaloid,Cycle specific and phase specific, which blocks mitosis 
in metaphase.Binds to icrotubular protein,tubulin,GTP dependent.Blocks 
the ability of tublin to polymerise to form microtubules ,which leads to 
rapid cytotoxic effects and cell destruction. 
 Onset of action :  15-30 mins 
 Duration of action : 19-155 hours 
 Special precautions in case of radiation therapy and concurrent 
vaccination 
 Cytocristin (Vincristine sulph – 1 mg, mannitol 100 mg, methylparaben 
0-13% 
 Prophyparaben 0.0.2% contain mannitol which can interact with 
cisplatin should be given through separate IV line) 
Dose : 1.5 mg/m2 (0.05 mg / kg/ dose – bolus IV for children younger than 36  
months and maximum dose 2mg) 
Preparations : 
 Cytocristin (Cipla) 1 mg inj Rs 45 
 Biocristin (Biochem) 1 ml inj. Rs 54 
Adverse effects 
 Local reaction (extravasation) 
 Constipation, Paralytic ileus 
 Alopecia 
 Jaw pain 
 Bone marrow depression, Peripheral neuropathy 
 Inappropriate ADH section 
 Shortness of breath, Bronchospasm 
 
PROFORMA 
 
 
Name     : ___________________________  
 
MRNo     :  
 
Age in months    :  
 
Sex     :   [ 1 - Male ; 2 - Female ] 
 
Eye Involved    :   [ 1 - RE ; 2 - LE ; 3 - BE ] 
  
Staging of eye according to  
New classification   : RE            LE             [A,B,C,D,E,F] 
 
Mode of presentation in patients :   ,        ,  
 
       [1 - Leucokoria ; 2 - Glaucoma ; 3 - Squint ; 4 - Proptosis ; 
       5 - Vitreous hemorrhage ; 6 - Hyphaema ; 7 - Hypopyon ; 
       8 - Defective vision ; 9 - No specific complaints ] 
 
Tumour features   :  ,               ,  
 
       [1 - Single tumour mass; 2 - Multiple tumour mass; 3 - RD; 
       4 - VH; 5 - VS; 6 – Optic Nerve infiltration;  
  7 - Orbital metatases ;  8 - Choroidal metatases ;  
  9 - Calcification; 10 - Retinal seedings ] 
 
Treatment administered  :       RE           LE 
      
       [1 – Enucleation ; 2 – Chemotherapy ; 3 – EBRT  
        4 – Local therapy; 5 – Excentration ] 
 
Chemotherapy status   :    [ 1 – Subjected to chemotherapy ; 
           2 – Not subjected to chemotherapy] 
 
Follow up    :    [ 1 – Completed Follow up ; 2 – No Follow up ] 
 
Tumour regression   :    [ 1 – Yes ; 2 No ]  
 
      
 
Leukocoria
MODES OF PRESENTATION
Orbital 
Cellulitis
Proptosis
Glaucoma
Retinoblastoma with 
Suprachiasmal Metastes
GROUP A
GROUP B
GROUP C
GROUP D
GROUP E
STAGING ACCORDING TO “NEW CLASSIFICATION”
POST TREATMENT FUNDUS PHOTOGRAPH
GROUP A
CRYOTHERAPY
GROUP A
PHOTOCOAGULATION
GROUP C
CHEMOTHERAPY 
WITH 
THERMOTHERAPY
DAY  1 AFTER  3 CYCLES
AFTER  4 CYCLES AFTER 5 CYCLES
AFTER 6 CYCLES AFTER 8 MONTHS REVIEW
Cottage cheese
Fish flesh Flat scar
EFFECT OF CHEMOTHERAPY
BILATERAL  RB
Prior To Treatment
Enucleated Left Eye
Gross Pathology
Before Chemotherapy
After Chemotherapy
Left Eye Artificial Eye
RB with 
Orbital Involvement
CT Scan Pictures showing Retinoblastoma
Bilateral RB with 
Meningeal Metastasis
Bilateral RB with 
Suprachiasmal Metastasis
Pre Treatment
Post Treatment
HISTOPATHOLOGY
Flexner wintersteiner
rosettes
Homer 
Wright rosettes
Gross Specimen
